Jules-Gonin Eye Hospital, Lausanne University, Lausanne, Switzerland.
Oncogenomic Laboratory, CHUV, Lausanne, Switzerland.
Ophthalmic Genet. 2021 Jun;42(3):354-359. doi: 10.1080/13816810.2021.1897847. Epub 2021 Apr 19.
: Absence of mutation is rare in retinoblastoma and MYCN amplifications were recently identified in a subset of aggressive retinoblastomas occurring in infants. Here we describe not only the clinical phenotype of MYCN retinoblastoma at presentation, but also the tumor response to the first attempt of conservative management in this context.: Interventional retrospective case report: A 6-month-old boy was referred with right leukocoria. Examination under anesthesia revealed a group D unilateral retinoblastoma with an extensive whitish mass and total retinal detachment. Despite partial response following combined sequential intravenous and intra-arterial chemotherapy, tumor relapse in the aqueous humor occurred with posterior chamber involvement over 360°, this transiently controlled by intracameral and intravitreal melphalan injections. Eleven months post-diagnosis the eye was enucleated due to diffuse retinal recurrence invading the ciliary body and obscuring the optic nerve, associated with neovascular glaucoma. Histopathology revealed a poorly differentiated retinoblastoma with diffuse retinal invasion, extending from the superior ciliary body to the inferior equatorial choroid. There was post laminar optic nerve extension without involvement of the surgical margin. RB1 and diffuse MYCN nuclear expression were identified. FISH and SNP-array confirmed MYCN amplification. At 65 months follow-up the patient remained in good health without local recurrence or metastasis.: To the best of our knowledge, this study is the first to attempt conservative management of an MYCN retinoblastoma, although secondary enucleation could not be avoided due to highly aggressive recurrence resisting all targeted modalities of chemotherapy.
:在视网膜母细胞瘤中很少出现突变,最近在发生于婴儿的侵袭性视网膜母细胞瘤亚组中发现了 MYCN 扩增。在此,我们不仅描述了 MYCN 视网膜母细胞瘤初次表现的临床表型,还描述了在这种情况下,肿瘤对首次尝试保守治疗的反应。:介入性回顾性病例报告:一名 6 月龄男孩因右眼白瞳而就诊。全身麻醉下检查发现右眼为 D 组单侧视网膜母细胞瘤,有广泛的白色肿块和全视网膜脱离。尽管联合序贯静脉和动脉内化疗后有部分缓解,但肿瘤在房水中复发,后房受累超过 360°,短暂地通过玻璃体内和眼内注射氨甲蝶呤得到控制。诊断后 11 个月,由于弥漫性视网膜复发侵犯睫状体并使视神经模糊,伴有新生血管性青光眼,眼球被摘除。组织病理学显示为分化不良的视网膜母细胞瘤,弥漫性视网膜侵犯,从睫状体上缘延伸至下赤道部脉络膜。后板层视神经延伸,但手术边缘无受累。RB1 和弥漫性 MYCN 核表达均被识别。FISH 和 SNP 芯片证实了 MYCN 扩增。在 65 个月的随访中,患者仍保持良好的健康状态,无局部复发或转移。:据我们所知,这是首例尝试对 MYCN 视网膜母细胞瘤进行保守治疗的研究,尽管由于高度侵袭性复发,所有靶向化疗方式均无效,最终仍不得不进行二次眼球摘除。